Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | The role of patients and patient groups in the European Reference Network EuroBloodNet

Joan Lluis Vives-Corrons and Pierre Fenaux • 9 Jun 2016
EHA 2016
General

Pierre Fenaux, MD, PhD of Saint-Louis Hospital & Paris Diderot University, Paris, France and Joan Lluis Vives-Corrons, MD, PhD from the Hospital Clinic Barcelona, Barcelona, Spain discuss the role of patients in the EuroBloodNet European Reference Network (ERN) on rare hematological diseases. First, they discuss the importance of the network for patients. According to Prof. Vives-Corrons, the most important objective of the network is to reduce the difference in quality of care between the different countries in Europe. Then, Prof. Fenaux and Prof. Vives-Corrons talk about the involvement and contribution of patient support groups to the network. Prof. Vives-Corrons highlights the empowerment of patients and how patients are key to the network and often very knowledgeable.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Joan Lluis Vives-Corrons

3:13
An overview of the European Reference Networks and EuroBloodNet
Joan Lluis Vives-Corrons et al. • 9 Jun 2016
3:16
EuroBloodNet European Reference Network - when will it be in place and why is collaboration crucial?
Joan Lluis Vives-Corrons et al. • 9 Jun 2016

More from Pierre Fenaux

9:38
Imetelstat provides durable transfusion independence in lower risk MDS group
Pierre Fenaux • 14 Jun 2019
3:13
An overview of the European Reference Networks and EuroBloodNet
Joan Lluis Vives-Corrons et al. • 9 Jun 2016
3:16
EuroBloodNet European Reference Network - when will it be in place and why is collaboration crucial?
Joan Lluis Vives-Corrons et al. • 9 Jun 2016

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals